"The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, a"...
- Patient Information:
Details with Side Effects
The acute toxicity of gefitinib up to 500 mg in clinical studies has been low. In nonclinical studies, a single dose of 12,000 mg/m² (about 80 times the recommended clinical dose on a mg/m²basis) was lethal to rats. Half this dose caused no mortality in mice.
There is no specific treatment for an IRESSA (getfitinib) overdose and possible symptoms of overdose are not established. However, in Phase 1 clinical trials, a limited number of patients were treated with daily doses of up to 1000 mg. An increase in frequency and severity of some adverse reactions was observed, mainly diarrhea and skin rash. Adverse reactions associated with overdose should be treated symptomatically; in particular, severe diarrhea should be managed appropriately.
IRESSA (getfitinib) is contraindicated in patients with severe hypersensitivity to gefitinib or to any other component of IRESSA (getfitinib) .
Last reviewed on RxList: 10/2/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Iressa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.